Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,123.55 +601.57 (+0.95%) CMC Crypto 200
1,334.09 +21.47 (+1.58%)
LLY Jan 2025 390.000 call
| Previous close | 383.29 |
| Open | 383.29 |
| Bid | 350.00 |
| Ask | 358.00 |
| Strike | 390.00 |
| Expiry date | 2025-01-17 |
| Day's range | 383.29 - 383.29 |
| Contract range | N/A |
| Volume | |
| Open interest | 157 |
ZacksPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
Insider Monkey13 Best Low Volatility Stocks to Buy According to Hedge Funds
In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]
BenzingaPatients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict. The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S’s (NYSE:NVO) Wegvoy (semaglutide) in 2021. Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA approval in November 2023. According to the FDA, limited supplies of Eli Lilly’s d
